Thousands of men with incurable prostate cancer will be offered a lifeline after an about-turn on NHS treatment.

Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today announces that the first patient has been dosed in the Phase 3 registration study of TLX591-Px (Illuccix®, Kit for the preparation ...

Because treatment of the whole prostate can lead to long-term side effects in patients with prostate cancer, interest in ...

Thousands of men in England living with advanced prostate cancer are poised to benefit from a new life-extending drug, ...

Decades ago, doctors created a test to determine which breast cancer patients should receive hormone therapy. Now, ...

To help meet the potentially complex needs of patients after prostate cancer treatment and offer the precision and care ...

Ernie Strauss and Ronald Wakefield, who met through the patient navigation program of Northside Hospital, have built a support network to help other men navigate the prostate cancer landscape.

In this analysis, researchers aimed to evaluate the clinicopathologic characteristics, metastatic patterns, and survival outcomes in patients with metastatic prostate cancer and low-volume primary ...

Abiraterone will be available in a matter of weeks and will be offered to 7,000 men a year.

An individual-patient meta-analysis sheds light on the optimal duration of androgen deprivation therapy in men with prostate cancer on definitive radiotherapy.

Because treatment of the whole prostate can lead to long-term side effects in patients with prostate cancer, interest in ...

A popular over-the-counter supplement that patients with cancer are prescribed or buy on their own to improve hair and nail ...